Original language | English |
---|---|
Pages (from-to) | 360-361 |
Number of pages | 2 |
Journal | Brain, Behavior, and Immunity |
Volume | 102 |
Early online date | 21 Mar 2022 |
DOIs |
|
Publication status | Published - May 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Brain, Behavior, and Immunity, Vol. 102, 05.2022, p. 360-361.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Scientists respond to the war in Ukraine – And so does BBI(H)
AU - Pariante, Carmine M.
N1 - Funding Information: Carmine Pariante is the Editor in Chief of Brain, Behavior and Immunity and of Brain, Behavior and Immunity – Health. He is supported by: a Senior Investigator award from the National Institute for Health Research (NIHR); the NIHR Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London; the Medical Research Council (grants MR/L014815/1, MR/J002739/1 and MR/N029488/1); the European Commission (EARLYCAUSE grant SC1-BHC-01-2019 and the Innovative Medicine Initiative 2 Joint Undertaking EUPEARL grant 853966); the NARSAD; the Psychiatry Research Trust; and the Wellcome Trust (SHAPER, Scaling-up Health-Arts Programme to scale up arts interventions, grant 219425/Z/19/Z). Less than 10% of his support in the last 10 years derives from commercial collaborations, including: a strategic award from the Wellcome Trust (Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium, grant 104025), in partnership with Janssen, GlaxoSmithKline, Lundbeck and Pfizer; a research grant from Janssen; and consultation and speakers fees from Boehringer Ingelheim, Eli Lilly, Compass, Eleusis, GH Research, Lundbeck, and Värde Partners. Funding Information: Carmine Pariante is the Editor in Chief of Brain, Behavior and Immunity and of Brain, Behavior and Immunity – Health. He is supported by: a Senior Investigator award from the National Institute for Health Research (NIHR); the NIHR Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London; the Medical Research Council (grants MR/L014815/1, MR/J002739/1 and MR/N029488/1); the European Commission (EARLYCAUSE grant SC1-BHC-01-2019 and the Innovative Medicine Initiative 2 Joint Undertaking EUPEARL grant 853966); the NARSAD; the Psychiatry Research Trust; and the Wellcome Trust (SHAPER, Scaling-up Health-Arts Programme to scale up arts interventions, grant 219425/Z/19/Z). Less than 10% of his support in the last 10 years derives from commercial collaborations, including: a strategic award from the Wellcome Trust (Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium, grant 104025), in partnership with Janssen, GlaxoSmithKline, Lundbeck and Pfizer; a research grant from Janssen; and consultation and speakers fees from Boehringer Ingelheim, Eli Lilly, Compass, Eleusis, GH Research, Lundbeck, and Värde Partners.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85126656058&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2022.03.012
DO - 10.1016/j.bbi.2022.03.012
M3 - Comment/debate
AN - SCOPUS:85126656058
SN - 0889-1591
VL - 102
SP - 360
EP - 361
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -